Reporter brief
A Phase II Randomized Placebo-Controlled Study of Fisetin and Exercise to Prevent Frailty in Breast Cancer Survivors
What happened
Trial registry update: RECRUITING. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- No sample size or effect size reported, preventing assessment of statistical power or magnitude of any observed benefit
- Phase II design means this is exploratory work; efficacy and safety endpoints are not specified in the abstract, so actual outcomes remain unknown
- The mechanism (senescent cell elimination) is stated as rationale but no biomarker data showing actual senescent cell reduction is mentioned
Study design and sample
Rct; Human.
Breast cancer survivors
- Design
- Rct
- Sample
- —
- Journal
- Jonsson Comprehensive Cancer Center
- Published
- Jul 30, 2026
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.